Site Map Press Room Careers
Business Strategy
Organizational Strengths
R & D Focus
Custom Synthesis
Customer Testimonials
Business Strategy

The robustness of business strategies are reviewed by the management at regular intervals. The business plans are modified and improvements made as an ongoing process.

The medium term strategy of Aurobindo Pharma is to continuously globalise the intellectual property assets and enhance value to shareholders and customers.

In global markets, the Company shall retain and enhance cost efficient quality leadership in semi synthetic penicillins, cephalosporins, newer anti infectives and lifestyle disease drugs. It is the endeavour of the Company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America.

Aurobindo Pharma shall repeat its success and emerge as a major player in regulated markets. The Company will obtain regulatory approvals by filing Drug Master Files (DMF) and Abbreviated New Drug Applications (ANDA) in lifestyle disease drugs and sterile and non-sterile cephalosporins having substantial entry barriers.

The Company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient mega manufacturing environment complying to US FDA and EU authorities.

The Company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aurobindo Pharma to acquire a significant part of bulk manufacturing of original research companies into its units.

The corporate plans are to ensure growth through organic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.
The long term growth strategies being put in to action include,
Develop a broad portfolio of DMFs/ANDAs through non-infringing processes and intellectual properties and become a significant player in the generics market, especially in the regulated markets.
Manage cost efficiently in a mega-manufacturing environment approved by USFDA/European regulatory authorities; and in the process, enhance the attractiveness of Aurobindo Pharma to alliance partners.
Resolve complex chemical challenges and offer advanced drugs to the global markets.
Globalise and further penetrate through joint ventures/subsidiaries/organic means into China, Brazil and other Latin American countries.
Emerge as a leading player in global high quality innovative speciality generic formulations and domestic brand segments.
Aurobindo will be good formulation company with the largest Active Pharmaceutical Ingredients manufacturer under CGMP qualified plant.

Director, Hanmi Pharm Co., Ltd, Korea
Site Map Press Room Careers